The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts tumour cell immunogenicity [1] [2] [3] [4] [5] [6] , but also as an extrinsic tumour suppressor that either destroys developing tumours or restrains their expansion 1, 2, 7 . Yet, clinically apparent cancers still arise in immunocompetent individuals in part as a consequence of cancer-induced immunosuppression. In many individuals, immunosuppression is mediated by cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), two immunomodulatory receptors expressed on T cells 8,9 . Monoclonal-antibody-based therapies targeting CTLA-4 and/or PD-1 (checkpoint blockade) have yielded significant clinical benefitsincluding durable responses-to patients with different malignancies [10] [11] [12] [13] . However, little is known about the identity of the tumour antigens that function as the targets of T cells activated by checkpoint blockade immunotherapy and whether these antigens can be used to generate vaccines that are highly tumour-specific. Here we use genomics and bioinformatics approaches to identify tumourspecific mutant proteins as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and we show that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy. Although mutant tumour-antigen-specific T cells are present in progressively growing tumours, they are reactivated following treatment with anti-PD-1 and/or anti-CTLA-4 and display some overlapping but mostly treatment-specific transcriptional profiles, rendering them capable of mediating tumour rejection. These results reveal that tumour-specific mutant antigens are not only important targets of checkpoint blockade therapy, but they can also be used to develop personalized cancer-specific vaccines and to probe the mechanistic underpinnings of different checkpoint blockade treatments.
In this study, we used two distinct progressor 3-methylcholanthreneinduced (MCA) sarcoma cell lines (d42m1-T3 and F244) and asked whether they expressed sufficient immunogenicity to be controlled by checkpoint blockade immunotherapy. Both sarcoma lines were rejected in wild-type mice treated therapeutically with anti-PD-1 and/or anti-CTLA-4 ( Fig. 1a ). Rejection was immunologic because (1) it was ablated by administration of monoclonal antibodies (mAbs) that either deplete CD4 1 or CD8 1 cells or neutralize interferon-c (IFN-c); (2) it did not occur in Rag2 2/2 mice lacking T, B and natural killer T (NKT) cells or Batf3 2/2 mice lacking CD8a 1 CD103 1 dendritic cells required for tumour antigen cross-presentation to CD8 1 T cells (Extended Data Fig. 1a ); and (3) it induced a memory response that protected mice against rechallenge with the same tumour cells that had been injected into naive mice (Extended Data Fig. 1b, c) .
On the basis of our previous success using genomics approaches to identify tumour-specific mutant antigens (TSMA) responsible for the spontaneous rejection of highly immunogenic, unedited MCA sarcomas 14 , we asked whether a similar approach could identify antigens responsible for anti-PD-1-mediated rejection of d42m1-T3 progressor tumours. To increase the robustness and accuracy of our epitope predictions, we modified our method as follows: (1) mutation calls from complementary DNA capture sequencing 14 were translated to corresponding protein sequences, pipelined through three major histocompatibility complex (MHC) class I epitope-binding algorithms and a median binding affinity was calculated for each predicted epitope; (2) epitopes were prioritized on the basis of predicted median binding affinities; and (3) filters were applied to the prioritized epitope list to eliminate those predicted to be poorly processed by the immunoproteasome and to deprioritize those from hypothetical proteins or those that displayed lower binding affinity to class I than their corresponding wild-type sequences. Using this approach, many epitopes were predicted for H-2D b (49,677 9-mer and 10-mer epitopes) (Extended Data Fig. 2a ) and H-2K b (44, 215 8-mer and 9-mer epitopes) ( Fig. 1b ) based on the 2,796 non-synonymous mutations expressed in d42m1-T3 14 . Focusing on epitopes with the highest predicted binding affinity to H-2D b or H-2K b , we narrowed the list down to four H-2D b -binding epitopes (Extended Data Fig. 2b ) and 62 H-2K bbinding epitopes (Fig. 1c ). Applying the aforementioned filters eliminated two predicted strong-binding H-2D b epitopes (Extended Data Fig. 2c ) and 20 predicted strong-binding H-2K b epitopes ( Fig. 1d ) (epitope binding affinity distributions to different class I alleles are distict 15 ). Based on the resulting in-silico-generated epitope landscape, two predominant H-2K b restricted mutant epitopes were identified by their predicted binding affinities: an A506T mutation (ITYAWTRLRITYTW TRL) in asparagine-linked glycosylation 8 (alpha-1,3-glucosyltransferase) (Alg8) and a G1254V mutation (GGFNFRTLRVGFNFRTL) in laminin alpha subunit 4 (Lama4). Based on H-2K b consensus binding, the mutations that produce these epitopes occur at positions p4 (Alg8) and p1 (Lama4). Neither functions as an anchor residue for H-2K b (these occur at p5 and p8). The mutant Alg8 (mAlg8) and mutant Lama4 (mLama4) epitopes are predicted to bind 1.2-and 12.8-fold stronger to H-2K b , respectively, compared to wild-type sequences.
To identify which of the predicted d42m1-T3 neoepitopes functioned as targets for CD8 1 T cells in anti-PD-1-treated, tumour-bearing mice, freshly explanted CD8 1 tumour-infiltrating lymphocytes (TIL) were isolated just before tumour rejection (day 11) and stained with fluorescently labelled H-2K b or H-2D b tetramers loaded with their corresponding strong-binding 66 predicted mutant epitopes. The only tetramer-positive T cells consistently identified in the CD8 1 TIL population were those reacting with mLama4-H-2K b tetramers (13.1% of CD8 1 TIL in experiment shown; 15.6 6 2.7% as the mean of 6 experiments) or mAlg8-H-2K b tetramers (4.2% of CD8 1 TIL in experiment shown; 2.8 6 1.1% as the mean of 6 experiments) ( Fig. 1e and Extended Data Fig. 2d ). Similar results were obtained when freshly explanted CD8 1 TIL from the same mice were co-cultured with naive irradiated splenocytes pulsed with each of the 66 predicted H-2K b and H-2D b epitopes. The mLama4 and mAlg8 epitopes were, again, the only significant hits, inducing IFN-c and tumour necrosis factor-a (TNF-a) production ( Fig. 1f and Extended Data Fig. 2e ). These results demonstrate that d42m1-T3 expresses two dominant TSMA epitopes for CD8 1 T cells following anti-PD-1 immunotherapy.
To independently validate these observations, we established CD8 1 T cell lines from spleens of mice that had rejected d42m1-T3 tumours after anti-PD-1 treatment. These T cells produced IFN-c when cocultured with d42m1-T3 but not when co-cultured with F244 or other independent sarcoma lines (Extended Data Fig. 3a ). Stimulation was restricted by H-2K b but not by H-2D b . The only predicted epitopes that stimulated these T cell lines were mLama4 and mAlg8 (Extended Data Fig. 3b ), but not their wild-type forms (Extended Data Fig. 4a ).
Four subsequent findings supported the conclusion that mLama4 and mAlg8 were the relevant antigens responsible for anti-PD-1-induced rejection of d42m1-T3. First, mLama4 or mAlg8 epitopes stabilized H-2K b expression on RMA-S cells, which lack a functional antigen transporter and thus fail to stably express MHC class I proteins on the cell surface (Extended Data Fig. 4b ). Second, both epitopes were detected by mass spectrometry in eluates of affinity-purified H-2K b isolated from d42m1-T3 tumours. Using a discovery mass spectrometry approach, we identified mLama4 in the H-2K b eluate (Extended Data Fig. 5a ) and verified its identity using an isotope-labelled synthetic mLama4 peptide 
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(Extended Data Fig. 5b ). We also found more than 200 wild-type peptides associated with H-2K b (Supplementary Table 1 ), but we have no evidence that any of these function as d42m1-T3 antigens. Mutant Alg8, wild-type Lama4 and wild-type Alg8 peptides were not detected (Supplementary Table 1 ). In contrast, using the more sensitive targeted selected reaction monitoring (SRM) mass spectrometry method, both mLama4 and mAlg8 peptides were identified in the H-2K b eluate ( Fig. 2a , Extended Data Fig. 6a and Supplementary Data 1). Notably, mLama4 and mAlg8 were the only predicted strong-binding mutant epitopes found. Peptides from wild-type Lama4 or wild-type Alg8 were not detected. Neither mLama4 nor mAlg8 were detected in H-2K b eluates from F244 cells (Extended Data Fig. 6b ). Third, as detected by staining with H-2K b -mLama4 or -mAlg8 tetramers, CD8 1 T cells specific for either antigen accumulated temporally in d42m1-T3 tumours of anti-PD-1-treated mice, reaching maximal values just before tumour rejection ( Fig. 2b and Extended Data Fig. 7a ). No mLama4-or mAlg8-tetramer-positive TIL were observed in F244 sarcomas from anti-PD-1-treated mice. Fourth, the two H-2K b -restricted epitopes induced antigen-specific CD8 1 T cell responses in naive mice when injected together with polyinosinicpolycytidylic acid (poly(I:C)) as assessed by ELISPOT ( Fig. 2c ).
Since mLama4-and mAlg8-specific T cells were linked to anti-PD-1-induced d42m1-T3 rejection we asked whether a therapeutic vaccine comprised of these antigens could protect against tumour outgrowth. When 10-member groups of mice bearing established d42m1-T3 tumours were vaccinated with the combination of mLama4 (28-mer) and mAlg8 (21-mer) synthetic long peptides (SLPs) with poly(I:C), 9 rejected their tumours compared to control mice vaccinated with irrelevant human papilloma virus (HPV) (30-mer) SLP plus poly(I:C) (1/10 mice survived) or poly(I:C) alone (1/10 mice survived) ( Fig. 2d and Extended Data Fig. 8a ). In multiple experiments, mice vaccinated with mLama4 1 mAlg8 SLP 1 poly(I:C) displayed an 85% survival (17/20) whereas those treated with HPV SLP 1 poly(I:C) or poly(I:C) alone showed 10% (2/20) and 15% (3/20) survival, respectively ( Fig. 2e ). Prophylactic administration of the combined mLama4 and mAlg8 SLP vaccine induced 88% survival (15/17) (Extended Data Fig. 8b , c). The combined mLama4 and mAlg8 prophylactic SLP vaccine induced superior protection compared to either SLP alone (Extended Data Fig. 8c ) or compared to vaccines comprised of the minimal 8 amino acid epitopes (Extended Data Fig. 8c ). The d42m1-T3-specific vaccines did not prevent outgrowth of unrelated F244 sarcomas ( Fig. 2e and Extended Data Fig. 8c ). These results not only demonstrate that mLama4 and mAlg8 are major antigenic targets that mediate checkpoint blockade-induced rejection of d42m1-T3 tumours, but also show that anti-PD-1 or therapeutic SLP vaccines consisting of the TSMA targeted by anti-PD-1 are similarly efficacious. antigen-specific CD8 1 T cells. a, b, Top, per cent of CD8 1 TIL specific for mLama4 (a) or mAlg8 (b) following checkpoint blockade therapy. Bottom, mean number of mLama4-(a) or mAlg8-specific (b) CD8 1 TIL per tumour following checkpoint blockade therapy. N 5 5 mice per group pooled. Data are means 6 s.e.m. of at least three independent experiments. Samples were compared to control mAb treatment using unpaired, two-tailed Student's t test (*P , 0.05, **P , 0.01). c, Venn diagram revealing relationships between differentially expressed genes (P , 0.05) in mLama4-specific CD8 1 TIL from mice treated with checkpoint-blocking mAbs versus control mAb. d, Heat map showing differentially expressed genes (P , 0.05) in mLama4-specific CD8 1 TIL from mice treated with checkpoint-blocking versus control mAbs. Colour pattern is relative with respect to the row, with red indicating gene upregulation and blue indicating gene downregulation. n 5 15 mice per group analysed in triplicate. Data represent average tumour diameter 6 s.e.m. and are representative of at least three independent experiments. c, IFN-c ELISPOT analysis of peptidestimulated splenocytes from mice immunized with mLama4 or mAlg8 SLP plus poly(I:C) (n 5 3 mice per group). Data are means 6 s.e.m. Representative of two independent experiments. Samples were compared using unpaired, two-tailed Student's t test (*P , 0.05, **P , 0.01). d, Kaplan-Meier survival curves of d42m1-T3-tumour-bearing mice (10 mice per group) therapeutically vaccinated with SLP vaccines plus poly(I:C). mLama4 plus mAlg8 compared to HPV control: P 5 0.0002 (log-rank (Mantel-Cox) test). Representative of two independent experiments. e, Cumulative data from two independent SLP therapeutic vaccine experiments using mice (7-10 per group) with d42m1-T3 or F244 tumours.
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Since the aforementioned analyses were conducted using anti-PD-1treated mice bearing d42m1-T3 tumours, we asked whether the presence of mLama4-and mAlg8-specific T cells in the TIL population was dependent on checkpoint blockade therapy. T cells specific for mLama4 or mAlg8 were detected in mice treated with control mAb or anti-PD-1 and/ or anti-CTLA-4 ( Fig. 3a, b and Extended Data Fig. 7b ). The percentage and total number of mLama4-or mAlg8-specific CD8 1 TIL were similar in tumours from control mAb-and anti-PD-1-treated mice but were elevated in mice treated with either anti-CTLA-4 or anti-CTLA-4 1 anti-PD-1.
The observation that mLama4-and mAlg8-specific T cells were found in tumours from mice treated with either control mAb or checkpoint blockade mAbs prompted us to assess the resultant changes in the TIL population following anti-PD-1 and/or anti-CTLA-4 treatment. We used RNA sequencing (RNA-Seq) to assess gene expression in freshly isolated, mLama4-H-2K b -tetramer 1 TIL from groups of tumour-bearing mice treated with control mAb, anti-PD-1, anti-CTLA-4 or anti-PD-1 1 anti-CTLA-4. Since mLama4-specific T cells were seven times more abundant in d42m1-T3 tumours than mAlg8-specific T cells in this series of experiments, we restricted our analysis to the former. Only a subset of 25 genes was commonly regulated (either up or down) by treatment with anti-PD-1 and/or anti-CTLA-4 ( Fig. 3c and Extended Data Table 1a ). This group included a subset of genes whose enhanced expression is similar to that observed in CD8 1 T cells from mice during acute secondary viral infection and depressed in a manner similar to that of exhausted CD8 1 T cells in chronic viral infection 16 (Fig. 3c , Extended Data Table 1a and Supplementary Table 2 ). In contrast, antigen-specific CD8 1 TIL isolated from anti-PD-1 and/or anti-CTLA-4 treated mice displayed mostly treatment-specific alterations of non-overlapping sets of genes involved in CD8 1 T cell effector functions (Supplementary Table 2 ). The effects of checkpoint blockade on gene expression were predominantly observed on TSMA-specific T-cells and not in other CD8 1 TIL (Fig. 3d) .
To determine which pathways were regulated by the different checkpoint blockade therapies, we performed gene set enrichment analysis (GSEA) using canonical-pathway-and immunological-signature-databases. When compared to mLama4-specific TIL from control mAb-treated mice, tumour-antigen-specific TIL from mice treated with anti-PD-1 and/or anti-CTLA-4 displayed a common set of alterations involving effector function, MAPK, chemokine and cytokine receptor signalling (Extended Data Table 1b and Supplementary Table 3 ). In contrast, mLama4-specific TIL from mice treated with anti-PD-1, anti-CTLA-4 or both mAbs displayed profound treatment-specific pathway alterations (Extended Data Table 1b and Supplementary Table 3 ). Treatment with anti-PD-1 produced metabolic changes including those involving oxidative phosphorylation, glycolysis, respiratory electron transport, tricarboxylic acid cycle and pentose phosphate pathways, as well as in pathways involved in IL-2 signalling. These cells also displayed a profile consistent with response to type I IFN. Treatment with anti-CTLA-4 increased NFAT and JAK-STAT signalling pathway activity, cellular proliferation/cell cycle, and activation of effector T cells. Treatment with both anti-CTLA-4 and anti-PD-1 induced a synergistic pattern of metabolic and effector T-cell-specific functions, including those involving T-cell-mediated anti-tumour activity. This was reflected in the most significant enhancement of effector molecules such as IFN-c, Granzyme A, Granzyme B, and Fas ligand ( Supplementary Table 2 ). Thus, whereas blockade of different inhibitory co-stimulators leads to a common biological outcome-tumour eradication-the precise mechanisms by which this outcome is achieved differ.
We also assessed changes in expression of functionally relevant proteins on/in CD8 1 TIL in mice undergoing treatment with different checkpoint-blocking mAbs. TIL specific for mLama4 or mAlg8 from mice treated with anti-PD-1 and/or anti-CTLA-4 displayed lower cell surface expression of lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin and mucin protein 3 (TIM-3) than those in progressively growing tumours in control mAb-treated mice ( Fig. 4a and Extended Data Fig. 9a, b ). Elevated LAG-3 and TIM-3 expression is known to mark antigen-experienced, dysfunctional (that is, exhausted) CD8 1 T cells 16, 17 in chronic viral infection. Conversely, TIL specific for mLama4 or mAlg8 from anti-CTLA-4-or anti-CTLA-4 1 anti-PD-1-treated mice displayed significantly higher levels of Granzyme B than antigen-specific TIL from mice treated with either anti-PD-1 alone or control mAb (Fig. 4b) . Consistent with the RNA-Seq analysis, these changes were observed predominantly in antigen-specific TIL. In addition, whereas a low percentage of CD8 1 TIL from mice treated with control mAb produced IFN-c and TNF-a ( Fig. 4c and Extended Data Fig. 9c ), the percentage of IFN-c-producing TIL increased following treatment of the mice with anti-PD-1 and particularly with anti-CTLA-4 or the combination of anti-CTLA-4 1 anti-PD-1. TIL expressing both cytokines, which are likely to represent the most potent anti-tumour effectors, were most highly represented following treatment of tumour-bearing mice with the combination of anti-CTLA-4 1 anti-PD-1.
This report documents that TSMA are targets of checkpoint blockade immunotherapy and can be used in vaccines that therapeutically induce tumour rejection as effectively as checkpoint blockade therapy. The ability to rapidly and accurately identify TSMA using genomics and bioinformatics approaches [18] [19] [20] and use them to generate MHC tetramers to identify tumour-specific T cells provides a significant advantage to the fields of tumour immunology and cancer immunotherapy. This approach has not only facilitated the identification of the antigenic targets of T cells affected by checkpoint blockade therapy 21 
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also has provided insights into the molecular changes that occur within the tumour-antigen-specific T-cell population that give rise to the antitumour effects of anti-PD-1 and/or anti-CTLA-4. Our findings provide some of the first experimental support for the clinical observations that (1) checkpoint blockade therapy amplifies, in some cases, preexisting anti-tumour T-cell responses 8,9,21,22 ; (2) whereas anti-CTLA-4 treatment eliminates regulatory T cells, promotes T-cell priming, and renders the host more susceptible to autoimmunity 13, 22, 23 , anti-PD-1 promotes T-cell activation acting as a rheostat of immune effector function 9, 22, 24, 25 ; and (3) dual blockade of CTLA-4 and PD-1 is particularly effective in promoting enhanced anti-tumour effector functions 10, 22, 26 .
The mutational loads of the MCA sarcomas used in this study are high and similar to those of ultraviolet-and carcinogen-induced human cancers. For these types of tumours, it is likely that TSMA vaccines targeting multiple antigens will be possible, thereby providing better coverage of the tumour cell population in part due to dealing more effectively with tumour heterogeneity 27, 28 . Additionally, the combination of a TSMA vaccine and checkpoint blockade may facilitate the immune system's ability to recognize less immunogenic TSMA as well as shared, tumour-associated antigens (TAA) via mechanisms that mimic epitopespreading 29 . However, recent studies have shown that human tumours containing far fewer mutations (for example, 26 mutations) can be sensitive to TSMA-based immunotherapy even for tumour-specific antigens that are targets for class II restricted CD4 1 T cells 30 . Our study thus provides a strong argument to actively pursue the use of TSMA as targets for cancer immunotherapy, as a means to identify patients who would best benefit from such therapy, and as components of MHC tetramers that can be used to identify tumour-specific T cells as biomarkers of successful anti-tumour responses.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
Supplementary Information is available in the online version of the paper.
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METHODS
Mice. Wild type and Rag2 2/2 mice were purchased from Taconic Farms. Batf3 2/2 mice 31 on a 129S6 background were provided by K. M. Murphy and were bred in our specific-pathogen free animal facility. All in vivo experiments used 8-12-weekold male, 129S6 background mice (to match the sex and strain of the tumours) housed in our specific-pathogen free animal facility. All studies were performed in accordance with procedures approved by the AAALAC accredited Animal Studies Committee of Washington University in St Louis. Tumour transplantation. MCA-induced sarcomas used in this study were generated in male 129S6 strain wild-type or Rag2 2/2 mice and were banked as lowpassage tumour cells as previously described 1 . All cell lines used in this study were tested for mycoplasma. Tumour cells derived from frozen stocks and propagated in vitro in RPMI media (Hyclone) supplemented with 10% FCS (Hyclone) were washed extensively, resuspended at a density of 6.67 3 10 6 cells ml 21 in endotoxinfree PBS and then 150 ml were injected subcutaneously into the flanks of recipient mice. Tumour cells were .90% viable at the time of injection as assessed by trypan blue exclusion. Tumour growth was quantified by calliper measurements and expressed as the average of two perpendicular diameters. Tumour growth measurements were performed blinded. Sample size was chosen based on extensive previous work with this animal model. No randomization was used. For antibody depletion studies, 250 mg of control mAb (PIP), anti-CD4 (GK1.5) or anti-CD8a (YTS169.4) was injected intraperitoneally into mice at day 21 and every 7 days thereafter. MHC class I epitope prediction. All missense mutations for d42m1-T3 were analysed for the potential to form MHC class I epitopes that bind to either H-2D b or H-2K b molecules. The Stabilized Matrix Method (SMM) algorithm 32 , the Artificial Neural Network (ANN) algorithm 33 , and the NetMHCpan algorithm 34 provided by the Immune Epitope Database and Analysis Resource (http://www.immuneepitope. org) was used to predict epitope processing and binding affinities and the results were ultimately expressed as affinity values (1/IC 50 3 100; where IC 50 is the halfmaximum inhibitory concentration). The median affinity value was calculated by taking the median of the predicted affinity values from SMM, ANN, and NetMHCpan algorithms. For the prediction of epitope processing, the NetChop algorithm 35 available from http://www.immuneepitope.org was used and potential epitopes were filtered with those with a NetChop score of 0.6 or higher being prioritized. Filters were also applied to eliminate mutations occurring in hypothetical Riken proteins and to de-prioritize mutations resulting in affinity values that were less than that predicted for the wild-type sequence. Antibodies. Anti-H-2K b (B8-24-3) and anti-H-2D b (B22/249) antibodies were provided by T. H. Hansen (Washington University School of Medicine). Anti-PD-1 (rat chimaeric murine IgG1 clone 4H2) and anti-CTLA-4 (murine IgG2b clone 9D9) antibodies were provided by A. J. Korman (Bristol-Myers Squibb). Isotype control antibodies (mouse IgG2a OKT3 and mouse IgG1 GIR-208) were purchased from Bio X Cell and Leinco Technologies, respectively. Anti-CD4 (GK1.5), anti-CD8a (YTS169.4), anti-IFN-c (H22) monoclonal antibodies and control immunoglobulin (PIP, a monoclonal antibody specific for bacterial glutathione S-transferase) were produced from hybridoma supernatants and purified in endotoxin-free form by Protein G affinity chromatography (Leinco Technologies). Fluorescently conjugated antibodies against CD3e, CD4, CD8, CD45, LAG-3, TIM-3, PD-1, IFN-c, and TNF-a were purchased from BioLegend. For tetramer staining, an antibody to CD8 was purchased from Accurate Chemical (clone CT-CD8a) as recommended for use with tetramer staining by the NIH Tetramer Core Facility at Emory. Fc block (anti-CD16/32) was purchased from BD Bioscience. Peptides. All 8-, 9-, and 10-mer peptides were purchased from Peptide 2.0. All peptides were HPLC-purified to .95% purity. Peptides for vaccine experiments were synthesized at ISA Therapeutics B.V. The peptides were synthesized using solid phase Fmoc/tBu chemistry on a PTI Prelude peptide synthesizer and purified on a Gilson preparative HPLC system to .95% purity. The identity and purity of the peptides for vaccine experiments were confirmed with UPLC-mass spectrometry on a Waters Acquity UPLC/TQD system. Checkpoint blockade immunotherapy. Tumour cells were subcutaneously transplanted into mice at 1 3 10 6 cells in 150 ml into the flank. Mice were treated intraperitoneally with 200 mg anti-PD-1 or anti-CTLA-4, used alone or in combination on days 3, 6, and 9 post-tumour transplant. For controls, mice were injected with 200 mg each of IgG2a and IgG1 isotype control antibodies. Generation of CTL lines. To generate the d42m1-T3-specific CTL lines, wild-type mice were injected with 1 3 10 6 d42m1-T3 tumour cells and treated with anti-PD-1 that induced tumour rejection. Alternatively, wild-type mice were injected with 1 3 10 6 d42m1-T3 tumour cells and were not treated with anti-PD-1, leading to formation of progressively growing tumours that were then surgically resected. Fifty days later, these mice were subsequently rechallenged with 1 3 10 6 d42m1-T3 tumour cells, which were then rejected. In the case of either protocol, spleens from independent mice that rejected the tumour were harvested two weeks after rejection and CTL lines were established by stimulating 40 3 10 6 splenocytes with 2 3 10 6 d42m1-T3 tumour cells pre-treated for 48 h with 100 U ml 21 of recombinant murine IFN-c and then irradiated (100 Gy). Cultures were stimulated two more times with irradiated, IFN-c stimulated tumour cells plus irradiated splenocytes and then CD8 1 T cells were purified using magnetic beads (Miltenyi Biotec). Peptide binding assay. The peptide-MHC class I binding assay with RMA-S cells 36 was performed by incubating RMA-S cells with serial dilutions of peptides for 24 h. Cells were stained with mAbs against H-2K b and H-2D b followed by secondary PE-conjugated goat anti-mouse Ig (BD Biosciences) and analysed by flow cytometry. Tetramers. For determining kinetics of mLama4-or mAlg8-specific T-cell infiltration into tumours, H-2K b tetramers conjugated to phycoerythrin (PE) were prepared with mutant Lama4 or Alg8 peptides and produced by the NIH Tetramer Core Facility (Emory University). For screening H-2K b or H-2D b predicted epitopes, we generated peptide-MHC Class I complexes in house. The peptide-MHC class I complexes refolded with an ultraviolet-cleavable conditional ligand were prepared as described with modifications 37 (HiTrap Q HP, GE) , biotinylated, and purified by gel filtration FPLC. Ultraviolet-induced ligand exchange and combinatorial encoding of MHC Class I multimers was performed as described 38 , except that the peptide-MHC multimers used for flow cytometry staining were prepared by the addition of titrated amounts of streptavidin-fluorochrome in a 10 ml format 39 . Measurement of IFN-c production. To generate target cells, tumour cells were treated with 100 U ml 21 IFN-c for 48 h and irradiated with 100 Gy before use. CTL cells (20,000 cells) were co-cultured with tumour target cells (20,000 cells) in 96-well round-bottomed plates for 48 h in a total volume of 200 ml. For peptide stimulation of CTL lines, 100,000 naive irradiated (30 Gy) splenocytes were pulsed with various 8-or 9-mer peptides at 37u C for 1 h. Splenocytes were washed and 20,000 CTLs were added and the culture was incubated for 48 h. IFN-c in supernatants was quantified using an IFN-c ELISA kit (eBioscience). For blocking assays, 25 mg ml 21 of anti-H-2K b (B8-24-3) or anti-H-2D b (B22/249) were added to the target cells (tumours) for 1 h before addition of CTL cells. For IFN-c ELISPOT, pre-coated 96well PVDF filtration plates (Millipore) were washed with PBS and conditioned with medium containing 10% FCS. Erythrocyte-free single-cell suspensions from the spleen were added in triplicate and incubated for 20 h with 1 mM mutant or wildtype peptide. After extensive washes, 1 mg ml 21 biotinylated detection antibody was added. Streptavidin-alkaline phosphatase and 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) (Moss Substrates) were subsequently used for colour development. Plates were scanned and analysed on an ImmunoSpot reader (C.T.L.). Reagents for ELISPOT were purchased from Mabtech. Tumour and spleen harvest. Established tumours were excised from mice, minced and treated with 1 mg ml 21 type IA collagenase (Sigma) in HBSS (Hyclone) for 1 h at 37 uC. Spleens were also harvested, crushed and vigorously resuspended to make single-cell suspensions. To remove aggregates and clumps, cells were filtered through a 40-mm strainer. CD8 1 TIL peptide restimulation. Cells from tumours were enriched for CD8 1 cells using Miltenyi mouse CD8 1 enrichment kit by following manufacturer's protocol. Splenocytes harvested from naive mice were labelled with CFSE and irradiated at 30 Gy. 100,000 labelled irradiated splenocytes were then pulsed with 1 mM of peptide and 100,000 CD8 1 TIL were subsequently added and incubated at 37 uC. After 1 h, BD GolgiPlug (BD Bioscience) was added and cells were incubated for an additional 4 h. Surface staining was performed and cells were then fixed and permeabilized with BD Cytofix/Cytoperm kit. Cells were then stained for IFN-c and TNF-a. Isolation of H-2K b presented peptides. For H-2K b isolation, sarcoma cell lines d42m1-T3 and F244 were each expanded to 5 3 10 8 cells. Prior to harvesting, cells were stimulated with 300 U ml 21 IFN-c for 48 h to increase MHC expression. Detachment of cells was facilitated by incubation with 100 U ml 21 Collagenase IV (Gibco) in PBS for 10 min at 37 uC in a 5% CO 2 incubator. Cells were washed twice with PBS and cell pellets were subsequently snap frozen. MHC class I molecules were isolated as previously described 40 . In brief, cell pellets were taken up in 1 ml of lysis buffer (1.2% CHAPS (Applichem, Darmstadt, Germany), 13 Protease Inhibitor Cocktail (Roche) in PBS) and homogenized by sonication. Lysates were cleared from remaining cell debris by centrifugation (2,500g, 30 min) and passing through a 0.2-mm filter (Sartorius, Goettingen, Germany). MHC class I molecules were isolated by immunoaffinity purification using H-2K b -specific antibody Y3 covalently coupled to cyanogen bromide-activated Sepharose 4B (GE Healthcare). MHC molecules were eluted with 0.2% trifluoroacetic acid (TFA) and released peptides were further isolated by ultrafiltration through centricons with a 10-kDa cut-off RESEARCH LETTER membrane (Millipore, Schwalbach, Germany). Prior to LC-mass spectrometry analysis peptides were desalted using C18 Zip Tips (Millipore) according to manufacturer's instructions and volumes were adjusted by vacuum centrifugation. Identification of H-2K b peptides by discovery mass spectrometry. For the discovery mass spectrometry 41 , mass spectrometry analysis was performed on an LTQ OrbitrapXL hybrid mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped with a nanoelectron spray ion source coupled to a reverse-phase liquid chromatography UHPLC system (Ultimate 3000 RSLCnano, Dionex, Sunnyvale, CA, USA). Samples were injected onto a 75 mm 3 2 cm trapping column (Acclaim PapMap RSLC, Dionex) at a flow rate of 4 ml min 21 for 5.75 min. Peptides were then separated on a 50 mm 3 50 cm separation column (Acclaim PapMap RSLC, Dionex) at 50 uC in a column oven with a flow rate of 175 nl min 21 and a gradient ranging from 2.5 to 32% acetonitrile over 140 min. Data dependent acquisition was enabled using a top five method (the five most abundant ions with charges of 21 or 31 were selected for fragmentation during each scan cycle). Survey scans were performed in the Orbitrap at a resolution of 60,000 and a mass range of 350-600 m/z. Peptides were fragmented and analysed in the ion trap using collisioninduced dissociation (CID, normalized collision energy 35%, activation time 30 ms, isolation width, 2 m/z). Doubly charged masses for mLama4 and mAlg8 were prioritized for fragmentation using an inclusion list.
Data processing was performed with Proteome Discoverer 1.3 (Thermo Fisher) and Mascot search engine (Mascot 2.2.04, Matrix Science). Peak lists were searched against Swiss-Prot Mus musculus database (exported 10 September 2013, 16,633 reviewed protein sequences) extended with the 62 mutated H-2K b candidate sequences. Search restrictions were 5 p.p.m. precursor mass tolerance and 0.5 Da fragment mass tolerance with no enzymatic cleavage specificity selected. Percolator algorithm was used to evaluate false discovery rate with a target value of 0.05 (5% FDR). Additional post processing filters were an ion score $ 20, search engine rank 1 and peptide length between 8 and 12 amino acids. Identification of H-2K b peptides by targeted SRM. To generate the SRM 42 assay library, the synthetic peptides were first analysed on an AB Sciex QTRAP 5500 mass spectrometer in SRM-triggered MS2 mode. Peptides (PEPotec SRM Grade 2) were synthesized by Thermo Fischer Scientific GmbH (Ulm, Germany). 51 of the 62 strong binding H-2K b peptides were selected for analysis because they had physiochemical properties that would allow their detection by mass spectrometry if present. Chromatographic separations of peptides were performed by a nanoLC ultra 2Dplus system (Eksigent) coupled to a 15 cm fused silica emitter, 75 mm inner diameter, packed with a Magic C18 AQ 5 mm resin (Michrom BioResources). Peptides were loaded on the column from a cooled (4 uC) nanoLC-AS2 autosampler (Eksigent) and separated in 60 min by a linear gradient of acetonitrile (5-35%) and water, containing 0.1% formic acid at a flow rate of 300 nl min 21 . The mass spectrometer was operated in SRM mode, triggering acquisition of a full fragment ion spectrum upon detection of an SRM trace (threshold 1,000 ion counts). SRM acquisition was performed with Q1 and Q3 operated at unit resolution (0.7 m/z half maximum peak width) with a dwell time of 20 ms for each transition. For each peptide the first fragment ion of the y-series with an m/z above the m/z precursor 1 20 Thomson (Th), for the doubly charged peptide precursors, were used as triggering transitions. Tandem mass spectrometry spectra were acquired in enhanced product ion mode, using quadrupole (q2) fragmentation, low Q1 resolution, scan speed 10,000 Da s 21 , and an m/z range of 250-1,000. Collision energies (CEs) were calculated according to the formulas: CE 5 0.044 3 m/z precursor 1 5.5 for doubly charged precursor ions. Raw data files (wiff) were converted into mzXML format using msConvert from ProteoWizard (version 1.6.1455). Qtrap MS2 spectra were assigned to peptide sequences using the SEQUEST algorithm and PeptideProphet. The software Skyline 43 was used to generate a spectral library from the Qtrap mzXML files. Optimal SRM transition conditions (collision energy and fragment ion selection) were determined for individual peptides as previously described by using synthetic peptides 44 . Retention times were extracted from the spectra and converted into a system-independent retention time (iRT) using spiked-in calibration peptides (Biognosys) 45 . For each target mutant peptides, a heavy isotope-labelled reference peptides was spiked in the H-2K b peptide mixture for identification. For each peptide, three to seven transitions were monitored for the heavy and light version and the resulting SRM data were visualized and analysed manually by using the software Skyline. The unequivocal detection of mutant MHC Class I H-2K b -associated peptides was achieved by comparing three properties between the reference heavy isotope-labelled peptide and its endogenous version: (1) their retention time must be consistent, (2) they must trigger all SRM transitions concurrently and (3) SRM transitions must be in the correct abundance hierarchy. Fluorescence-activated cell sorting analysis. For flow cytometry, cells were stained for 5 min at room temperature with 500 ng of Fc block (anti-CD16/32) and then stained with 200 ng of antibodies to CD45, CD4 or CD8a in 100 ml of staining buffer (PBS with 2% FCS and 0.05% NaN 3 (Sigma)) for 20 min at 4 uC. Propidium iodide (PI) (Sigma) was added at 1 mg ml 21 immediately before FACS analysis. For tetramer staining, cells were stained for 5 min at room temperature with 500 ng of Fc block (anti-CD16/32). Cells were then stained with anti-CD8 antibody (clone CT-CD8a from Accurate Chemical) for 20 min at 4 uC at a 1:100 dilution. Antibodies to CD45 and CD3e along with H-2K b tetramers conjugated to PE were then added at a concentration of 1:100 for 30 min at 4 uC. For intracellular cytokine staining of tumourinfiltrating lymphocytes, cells were isolated incubated for 5 h with GolgiPlug (BD bioscience). Cells were then harvested, washed, stained with anti-CD3e and CD8a for 15 min, and then fixed and permeabilized with BD fixation and permeabilization kit (BD Biosciences). Cells with then stained with anti-IFN-c or anti-TNF-a. For sorting of mLama4-specific cells, tumour-infiltrating cells were enriched for CD45 1 cells using CD45 cell purification magnetic beads (Miltenyi Biotec). CD45enriched cells were then sorted gating for PI 2 CD3e 1 CD8a 1 mLama4-tetramer-PE 1 or PI 2 CD3e 1 CD8a 1 mLama4-tetramer-PE 2 cells. Sorting was performed on a BD FACSAria II (BD Biosciences). Sorted cells were pelleted and processed for RNA analysis. The purity of the sorted cells for input RNA was greater than 90% as assessed during post-sort cellular analysis. All flow cytometry was performed on the FACSCalibur (BD Biosciences) or LSR Fortessa (BD Biosciences) and analysed using FlowJo software (TreeStar). Vaccination. Mice were vaccinated subcutaneously with 50 mg peptides corresponding to mLama4 or mAlg8 in combination with 100 mg poly(I:C) (Sigma-Aldrich). For SLP, the mLama4 peptide sequence used was QKISFFDGFEVGFNFRTLQPN GLLFYYT (epitope underlined) and the mAlg8 peptide sequence used was AVGI TYTWTRLYASVLTGSLV (epitope underlined). Two weeks later spleens were harvested and splenocytes were restimulated with wild-type or mutant Lama4 or Alg8 8-mer peptides. Cells were then collected for ELISPOT analysis. For prophylactic vaccination, mice were subcutaneously injected with 50 mg of peptides corresponding to mLama4 or mAlg8, used alone or in combination, along with 100 mg of poly (I:C) in a total volume of 200 ml diluted in HBSS on day -10, -3, and 14 post-tumour transplant. d42m1-T3 tumour cells were transplanted at 1 3 10 6 tumour cells on day 0. As controls, mice were immunized with either HBSS alone, poly(I:C) alone or a long-peptide vaccine corresponding to human papilloma virus (HPV) with poly(I:C). Therapeutic vaccination experiments were performed in identical manner except vaccines were administered on day 13, 19, and 115 post-tumour transplant. Lack of survival was defined as mouse death or tumour size of 20 mm. RNA sequencing. The purity of the sorted cell preparations were greater than 90% as assessed by post-sort cellular analysis. mRNA was extracted from cell lysates using oligo-dT beads (Invitrogen). For cDNA synthesis, we used custom oligo-dT primers with a barcode and adaptor-linker sequence (CCTACACGACGCTCTTC CGATCT-XXXXXXXX-T15). After first strand synthesis, samples were pooled together based on Actb qPCR values and RNA-DNA hybrids were degraded using consecutive acid-alkali treatment. Then, a second sequencing linker (AGATCGG AAGAGCACACGTCTG) was ligated using T4 ligase (NEB) followed by SPRI cleanup. The mixture then was enriched by 16 cycles of PCR and SPRI purified to yield final strand specific RNA-seq libraries. The libraries were sequenced on a HiSeq 2500 instrument using 50 bp 3 25 bp pair-end sequencing. Second read-mate was used for sample demultiplexing, at which point individual single-end fastqs files were aligned to mm9 genome using STAR aligner with the following options-runThreadN 8-outFilterMultimapNmax 15-outFilterMismatchNmax 6-outReadsUnmapped Fastx-outSAMstrandField intronMotif-outSAMtype BAM SortedByCoordinate. Gene expression was quantitated using ht-seq and differentially expressed genes were defined using DESeq2 R package at P value ,0.01. Gene Set Enrichment Analysis (GSEA) using canonical pathway-and immunological signature-databases was performed as previously described 46 . Statistical analysis. Samples were compared using an unpaired, two-tailed Student's t-test, unless specified. Figure 1 | Innate and adaptive immune components are required for rejection of d42m1-T3 after checkpoint blockade therapy. a, Cohorts of Rag2 2/2 , Batf3 2/2 or wild-type mice were treated with control mAb, anti-CD4, anti-CD8a or anti-IFN-c mAbs and then were injected with 1 3 10 6 d42m1-T3 tumour cells subcutaneously and subsequently treated with anti-CTLA-4 on days 3, 6 and 9 post-transplant. b, c, d42m1-T3 (b) or F244 (c) tumour cells were injected subcutaneously into wild-type mice (n 5 5) that were subsequently treated with anti-PD-1 on days 3, 6, and 9. Fifty days after tumours were rejected, mice were rechallenged with d42m1-T3 or F244 tumour cells. Data are presented as average tumour diameter 6 s.e.m. of 5 mice per group and are representative of at least two independent experiments.
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Extended Data Figure 2 | H-2D b mutant epitopes of d42m1-T3 tumours. a, Missense mutations in d42m1-T3 were subjected to in silico analysis for the potential to form H-2D b -binding epitopes using three epitope prediction algorithms. The median predicted epitope-binding affinity for each peptide was calculated and expressed as 'median affinity value' where affinity value 5 1/IC 50 3 100. Predicted epitopes are arrayed along the x-axis in alphabetical order based on their protein of origin. b, Unfiltered median affinity values for the four predicted H-2D b epitopes. c, Median affinity values of remaining two H-2D b epitopes after filtering. d, Tetramer staining of CD8 1 TIL from tumour-bearing mice treated with anti-PD-1 using H-2D b tetramers loaded with top 4 H-2D b synthetic peptides. e, IFN-c and TNF-a intracellular cytokine staining of CD8 1 TIL from tumour-bearing mice treated with anti-PD-1 immunotherapy following co-culture with naive irradiated splenocytes pulsed with the top four H-2D b synthetic peptides added at 1 mM final concentration. Data are presented as per cent of CD8 1 TIL positive for IFN-c, TNF-a or both cytokines. Data are representative of two independent experiments.
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